ECSP055850A - Agonistas morfolinicos de la dopamina - Google Patents
Agonistas morfolinicos de la dopaminaInfo
- Publication number
- ECSP055850A ECSP055850A EC2005005850A ECSP055850A ECSP055850A EC SP055850 A ECSP055850 A EC SP055850A EC 2005005850 A EC2005005850 A EC 2005005850A EC SP055850 A ECSP055850 A EC SP055850A EC SP055850 A ECSP055850 A EC SP055850A
- Authority
- EC
- Ecuador
- Prior art keywords
- morpholinic
- dopamine
- agonists
- alkyl
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Reproductive Health (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Gynecology & Obstetrics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Addiction (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Pregnancy & Childbirth (AREA)
- Dermatology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
La presente invención proporciona compuestos de las fórmulas (I), (Ia) y (Ib) en las que:A se selecciona entre C-X y N,B se selecciona entre C-Y y N,R1 se selecciona entre H y alquilo C1-C6,R2 se selecciona entre H y alquilo C1-C6,X se selecciona entre H, HO, C(O)NH2, NH2,Y se selecciona entre H, HO, NH2, Br, Cl y F,Z se selecciona entre H, HO, F, CONH2 y CN;y sus sales, solvatos y profármacos farmacéuticamente aceptables;con las condiciones de que:para un compuesto de la fórmula (I), (Ia) o (Ib), cuando A es C-X, B es C-Y, R1 es H o alquilo C1-C6, y R2 es H o alquilo C1-C6, al menos uno de X, Y y Z debe ser OH;para un compuesto de la fórmula (I), cuando A es C-X y B es C-Y, Y es H, Z es H, R1 es H, y R2 es H, entonces X no puede ser OH.y estos compuestos son útiles como medicamentos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0228787A GB0228787D0 (en) | 2002-12-10 | 2002-12-10 | Morpholine dopamine agonists |
GB0308460A GB0308460D0 (en) | 2003-04-11 | 2003-04-11 | Morpholine dopamine agonists |
GB0313606A GB0313606D0 (en) | 2003-06-12 | 2003-06-12 | Morpholine dopamine agonists |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP055850A true ECSP055850A (es) | 2005-09-20 |
Family
ID=32512061
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2005005850A ECSP055850A (es) | 2002-12-10 | 2005-06-10 | Agonistas morfolinicos de la dopamina |
Country Status (37)
Country | Link |
---|---|
EP (1) | EP1572214B1 (es) |
JP (3) | JP3889775B2 (es) |
KR (1) | KR100796102B1 (es) |
AP (1) | AP2005003325A0 (es) |
AR (1) | AR042339A1 (es) |
AT (1) | ATE460938T1 (es) |
AU (1) | AU2003302878B2 (es) |
CA (1) | CA2508262C (es) |
CO (1) | CO5700781A2 (es) |
CR (1) | CR7869A (es) |
CY (1) | CY1110130T1 (es) |
DE (1) | DE60331769D1 (es) |
DK (1) | DK1572214T3 (es) |
EA (1) | EA009589B1 (es) |
EC (1) | ECSP055850A (es) |
ES (1) | ES2339767T3 (es) |
GE (1) | GEP20074272B (es) |
HK (1) | HK1081850A1 (es) |
HN (1) | HN2003000401A (es) |
HR (1) | HRP20050523A2 (es) |
IS (1) | IS7843A (es) |
MA (1) | MA27605A1 (es) |
MX (1) | MXPA05006151A (es) |
MY (1) | MY144338A (es) |
NL (1) | NL1024983C2 (es) |
NO (1) | NO330143B1 (es) |
NZ (1) | NZ540505A (es) |
OA (1) | OA13014A (es) |
PA (1) | PA8591601A1 (es) |
PE (1) | PE20040906A1 (es) |
PL (1) | PL377480A1 (es) |
PT (1) | PT1572214E (es) |
RS (1) | RS51442B (es) |
SI (1) | SI1572214T1 (es) |
TW (1) | TW200423944A (es) |
UY (1) | UY28117A1 (es) |
WO (1) | WO2004052372A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2568050A1 (en) * | 2004-05-26 | 2005-12-08 | Pfizer, Inc. | Indazole and indolone derivatives and their use as pharmaceuticals |
AU2005247699A1 (en) * | 2004-05-27 | 2005-12-08 | Pfizer Inc. | Aminopyridine derivatives as selective dopamine D3 agonists |
GB0502509D0 (en) * | 2005-02-07 | 2005-03-16 | Pfizer Ltd | Novel salt form of a dopamine agonist |
TW200740779A (en) | 2005-07-22 | 2007-11-01 | Mitsubishi Pharma Corp | Intermediate compound for synthesizing pharmaceutical agent and production method thereof |
GB0700786D0 (en) * | 2007-01-15 | 2007-02-21 | Pfizer Ltd | Morpholine dopamine agonists for the treatment of pain |
ES2546492T3 (es) | 2010-05-21 | 2015-09-24 | Research Triangle Institute | Derivados de 1-fenilmorfolina como análogos de hidroxibupropion para tratar drogodependencia |
ES2687095T3 (es) | 2010-05-21 | 2018-10-23 | Research Triangle Institute | Fenilimorfolinas y análogos de las mismas |
CN105793430B (zh) | 2013-12-11 | 2020-03-03 | 豪夫迈·罗氏有限公司 | 用于制备手性2-芳基吗啉的方法 |
GB2543296A (en) | 2015-10-13 | 2017-04-19 | Indivior Uk Ltd | Dopamine D3 receptor antagonists having a morpholine moiety |
EP3725768A1 (en) * | 2019-04-17 | 2020-10-21 | Newron Pharmaceuticals S.p.A. | Process for the production of substituted 2-[2-(phenyl) ethylamino]alkaneamide derivatives |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB851311A (en) * | 1958-04-02 | 1960-10-12 | Geigy Ag J R | Morpholine compounds and their production |
GB9108629D0 (en) * | 1991-04-23 | 1991-06-12 | Wellcome Found | Heterocyclic pharmaceutical compounds,preparation and use |
GB0130219D0 (en) * | 2001-12-18 | 2002-02-06 | Pfizer Ltd | Compounds for the treatment of sexual dysfunction |
-
2003
- 2003-12-02 WO PCT/IB2003/005683 patent/WO2004052372A1/en active Application Filing
- 2003-12-02 DK DK03812639.7T patent/DK1572214T3/da active
- 2003-12-02 DE DE60331769T patent/DE60331769D1/de not_active Expired - Lifetime
- 2003-12-02 NZ NZ540505A patent/NZ540505A/en not_active IP Right Cessation
- 2003-12-02 KR KR1020057010474A patent/KR100796102B1/ko not_active IP Right Cessation
- 2003-12-02 AT AT03812639T patent/ATE460938T1/de active
- 2003-12-02 OA OA1200500171A patent/OA13014A/en unknown
- 2003-12-02 AP AP2005003325A patent/AP2005003325A0/xx unknown
- 2003-12-02 JP JP2005502342A patent/JP3889775B2/ja not_active Expired - Fee Related
- 2003-12-02 PL PL377480A patent/PL377480A1/pl not_active Application Discontinuation
- 2003-12-02 GE GEAP20038838A patent/GEP20074272B/en unknown
- 2003-12-02 EP EP03812639A patent/EP1572214B1/en not_active Expired - Lifetime
- 2003-12-02 ES ES03812639T patent/ES2339767T3/es not_active Expired - Lifetime
- 2003-12-02 MX MXPA05006151A patent/MXPA05006151A/es active IP Right Grant
- 2003-12-02 PT PT03812639T patent/PT1572214E/pt unknown
- 2003-12-02 CA CA002508262A patent/CA2508262C/en not_active Expired - Fee Related
- 2003-12-02 RS YUP-2005/0445A patent/RS51442B/en unknown
- 2003-12-02 EA EA200500801A patent/EA009589B1/ru not_active IP Right Cessation
- 2003-12-02 AU AU2003302878A patent/AU2003302878B2/en not_active Ceased
- 2003-12-02 SI SI200331801T patent/SI1572214T1/sl unknown
- 2003-12-05 PE PE2003001234A patent/PE20040906A1/es not_active Application Discontinuation
- 2003-12-08 MY MYPI20034690A patent/MY144338A/en unknown
- 2003-12-09 AR ARP030104524A patent/AR042339A1/es unknown
- 2003-12-09 TW TW092134694A patent/TW200423944A/zh unknown
- 2003-12-09 HN HN2003000401A patent/HN2003000401A/es unknown
- 2003-12-10 UY UY28117A patent/UY28117A1/es not_active Application Discontinuation
- 2003-12-10 PA PA20038591601A patent/PA8591601A1/es unknown
- 2003-12-10 NL NL1024981A patent/NL1024983C2/nl not_active IP Right Cessation
-
2005
- 2005-05-12 IS IS7843A patent/IS7843A/is unknown
- 2005-05-26 NO NO20052557A patent/NO330143B1/no not_active IP Right Cessation
- 2005-06-09 HR HR20050523A patent/HRP20050523A2/hr not_active Application Discontinuation
- 2005-06-10 EC EC2005005850A patent/ECSP055850A/es unknown
- 2005-06-10 CR CR7869A patent/CR7869A/es unknown
- 2005-06-10 CO CO05056566A patent/CO5700781A2/es not_active Application Discontinuation
- 2005-06-10 MA MA28324A patent/MA27605A1/fr unknown
-
2006
- 2006-02-17 HK HK06102107.0A patent/HK1081850A1/xx not_active IP Right Cessation
- 2006-06-06 JP JP2006157609A patent/JP3920908B2/ja not_active Expired - Fee Related
- 2006-12-27 JP JP2006352505A patent/JP4624341B2/ja not_active Expired - Fee Related
-
2010
- 2010-04-26 CY CY20101100367T patent/CY1110130T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP055850A (es) | Agonistas morfolinicos de la dopamina | |
ES2509820T3 (es) | Derivados de indazol como inhibidores de la cinasa para el tratamiento del cáncer | |
ES2500068T3 (es) | Inhibidores heterocíclicos de MEK y métodos de uso de los mismos | |
ES2571779T3 (es) | Inhibidores de cinasa a base de nicotinamida | |
ES2485867T3 (es) | Compuestos opioides de carboxamido | |
CR9690A (es) | 3-acilaminobenzanilidas insecticidas | |
PE20081534A1 (es) | Piperidinas sustituidas que tienen actividad inhibidoras de la proteina cinasa | |
CO5550421A2 (es) | Derivados de indol utiles para el tratamiento de enfermeda- des | |
UY27918A1 (es) | Derivados de benzodioxol | |
ECSP055582A (es) | Derivados de benzotiazol que tienen actividad agonista de beta-2-adrenorreceptor | |
CO6321248A2 (es) | Derivados de triazol utiles para el tratamiento de enfermedades | |
UY28823A1 (es) | Compuestos de ácido alfa aril o heteroaril metil beta piperidino propanoico como antagonistas del receptor orl1 | |
ECSP099065A (es) | Derivados de cinamoil-piperazina y su utilización como antagonistas de par-1 | |
DOP2012000149A (es) | Compuestos triciclicos novedosos | |
AR068479A1 (es) | (carboxilalquilenfenil) feniloxamidas, procedimiento para su preparacion y una coomposicion farmaceutica | |
GT200300087A (es) | 2-(2,6-diclorofenil)-diarilimidazoles | |
NI200900021A (es) | Inhibidor de quinasa | |
ECSP088638A (es) | Bencensulfonil-cromano, tiocromano, tetrahidronaftaleno e inhibidores de gamma secretasa relacionados | |
AR083417A1 (es) | Composiciones farmaceuticas que contienen un dgat1 inhibidor | |
ECSP109919A (es) | Compuesto de piridacina cristalina | |
AR078278A1 (es) | Antagonistas de la tiazol y oxazol hepcidina, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento de anemias y enfermedades asociadas a deficiencias de hierro. | |
AR072904A1 (es) | Compuestos de fenilamino-isonicotinamida y composiciones farmaceuticas que los contienen | |
EA200900631A1 (ru) | Замещённые пиразолы и триазолы, как ингибиторы кбв (кинезин-белок веретена) | |
UY29749A1 (es) | Antagonistas de cgrp seleccionados, procedimientos para su preparación, así como su uso como medicamentos | |
CO5580821A2 (es) | 4-cetolactamas y -lactonas 3-fenil-3-substituidas, espirociclicas |